DBV Technologies (NASDAQ:DBVT) Announces Earnings Results

DBV Technologies (NASDAQ:DBVT) released its quarterly earnings data on Tuesday. The company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.26) by ($0.08), Yahoo Finance reports. The business had revenue of $1.16 million during the quarter, compared to analyst estimates of $1.42 million. DBV Technologies had a negative net margin of 530.89% and a negative return on equity of 56.76%. During the same quarter in the previous year, the company posted ($0.26) EPS.

DBV Technologies Stock Performance

Shares of NASDAQ DBVT traded up $0.00 during midday trading on Wednesday, reaching $0.95. 17,357 shares of the stock were exchanged, compared to its average volume of 55,614. The company has a 50 day simple moving average of $0.92 and a 200 day simple moving average of $1.33. The stock has a market capitalization of $91.62 million, a P/E ratio of -1.13 and a beta of 0.69. DBV Technologies has a twelve month low of $0.50 and a twelve month high of $3.70.

Analyst Upgrades and Downgrades

A number of research firms have commented on DBVT. HC Wainwright cut their price objective on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, May 8th. JMP Securities raised their price target on shares of DBV Technologies from $4.00 to $5.00 and gave the stock a “market outperform” rating in a report on Wednesday. Finally, StockNews.com started coverage on shares of DBV Technologies in a report on Thursday, July 25th. They set a “hold” rating for the company.

DBV Technologies Company Profile

DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis.